Literature DB >> 19945688

Secondary osteoporosis in patients with an osteoporotic fracture.

C Kok1, P N Sambrook.   

Abstract

Secondary osteoporosis is a common cause of osteoporosis, and there are many medical conditions associated with osteoporosis. Many of these present well before osteoporosis develops, and knowledge of these pre-existing conditions may influence the decision about whether to test and/or treat for osteoporosis. Men and premenopausal women with unexplained osteoporosis or a history of fragility fracture should undergo investigation for secondary osteoporosis. Postmenopausal women with risk factors for secondary osteoporosis should also be carefully evaluated. Beyond the well-recognised association with glucocorticoids, an increasing list of drugs has been implicated in causing bone loss and fractures. With appropriate consideration of secondary causes and relevant investigations, many of these conditions are preventable with newer therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19945688     DOI: 10.1016/j.berh.2009.09.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  15 in total

1.  Prevalence of less severe hypercortisolism in fractured patients admitted in an outpatient clinic for metabolic bone diseases.

Authors:  F Pugliese; A S Salcuni; C Battista; V Carnevale; G Guglielmi; C Columbu; F Velluzzi; L Giovanelli; C Eller-Vainicher; A Scillitani; I Chiodini
Journal:  Endocrine       Date:  2021-01-23       Impact factor: 3.633

2.  Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.

Authors:  I Baxter; A Rogers; R Eastell; N Peel
Journal:  Osteoporos Int       Date:  2012-08-08       Impact factor: 4.507

3.  Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.

Authors:  Quentin Dardonville; Esther Salguiero; Vanessa Rousseau; Leila Chebane; Jean Luc Faillie; Sophie Gautier; Jean Louis Montastruc; Alfonso Carvajal; Haleh Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

4.  Osteoporotic hip fractures in non-elderly patients: relevance of associated co-morbidities.

Authors:  Sandra G Pasoto; Liz A K Yoshihara; Lucy C Maeda; Marcia M S Bernik; Paulo A Lotufo; Eloisa Bonfa; Rosa M R Pereira
Journal:  Rheumatol Int       Date:  2011-09-27       Impact factor: 2.631

5.  Mutational analysis uncovers monogenic bone disorders in women with pregnancy-associated osteoporosis: three novel mutations in LRP5, COL1A1, and COL1A2.

Authors:  S Butscheidt; A Delsmann; T Rolvien; F Barvencik; M Al-Bughaili; S Mundlos; T Schinke; M Amling; U Kornak; R Oheim
Journal:  Osteoporos Int       Date:  2018-03-29       Impact factor: 4.507

6.  Optimizing screening for osteoporosis in patients with fragility hip fracture.

Authors:  Archana Roy; Michael G Heckman; Mary I O'Connor
Journal:  Clin Orthop Relat Res       Date:  2011-07       Impact factor: 4.176

Review 7.  Antiresorptive therapies for osteoporosis: a clinical overview.

Authors:  Jian Sheng Chen; Philip N Sambrook
Journal:  Nat Rev Endocrinol       Date:  2011-09-06       Impact factor: 43.330

8.  Vitamin E as an Antiosteoporotic Agent via Receptor Activator of Nuclear Factor Kappa-B Ligand Signaling Disruption: Current Evidence and Other Potential Research Areas.

Authors:  Kok-Yong Chin; Soelaiman Ima-Nirwana
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-02       Impact factor: 2.629

Review 9.  Glucocorticoid-induced osteoporosis.

Authors:  Karine Briot; Christian Roux
Journal:  RMD Open       Date:  2015-04-08

Review 10.  Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials.

Authors:  Shuang Tan; Binbin Zhang; Xiaomei Zhu; Ping Ao; Huajie Guo; Weihong Yi; Guang-Qian Zhou
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.